Tests a brain stimulation device for people with glaucoma
Tests repeated brain stimulation with a device in people with glaucoma.
Plain-language title generated from the registry record
Registry title: Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies
Key facts
- Where
- Taipei, TaiwanSee the site
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT07145073
- Record updated
- 30 January 2026
- Original description
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.Read full original descriptionShow less
Repetitive Transcranial Alternating Current Stimulation(rtACS) for the Treatment of Optic Neuropathies
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.
Inclusion: Participant must be at least 18; Clinical diagnosis of glaucoma, with Humphrey Visual Field 24-2 mean deviation (MD) between -22 dB and -5 dB, and Visual Field Index (VFI) between 10% and 90%. The visual field test at screening must meet the following reliability indices:; Fixation losses (FL) ≤ 33%; False-negative rate (FNR) ≤ 20%; False-positive rate (FPR) ≤ 20% At initial screening, the difference in MD between two consecutive visual field tests must be less than 2 dB; Best-corrected visual acuity (BCVA) ≥ 0.2 in the worse eye selected for stimulation treatment; If a participant has two eyes meeting study criteria, one eye will be randomly selected by computer for study participation; In the opinion of the investigator the participant's eye pressure must be clinically stable; Participant must has the ability to comply with the requirements of the study and complete the schedule of events; Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety; Optical coherence tomography (OCT) imaging shows measurable changes in either peripapillary retinal nerve fiber layer (RNFL) thickness or macular ganglion cell-inner plexiform layer thickness.
Exclusion: Brain tumor or intracranial magnetic metallic implants; Participation in another clinical trial within the past 3 months involving medication or training that could affect the eyes; Previous ocular electrical stimulation treatment or visual training study within the past 12 months; History of ocular herpes; Retinal disease sufficient to affect vision; Uveitis or other intraocular inflammatory disease; Rheumatologic or autoimmune disease; History of epilepsy; History of claustrophobia; Physical or mental conditions that may increase the risk of participation or interfere with study assessments (e.g., dementia); Uncontrolled hypertension or diabetes; History of craniotomy, burr hole surgery, head trauma, intracranial tumor, vascular malformation, or intracranial surgery; Pathological nystagmus; Corneal opacity affecting vision; Cataract affecting vision; Implanted electronic devices such as a pacemaker; Periocular skin lesions; Anxiety with Geriatric Anxiety Scale score > 12; Pregnant or breastfeeding.